Karyopharm Therapeutics | KPTI - Trade Creditors


Karyopharm Therapeutics reported $4M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Abbott USD 4.24B 117M Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
MacroGenics USD 4.29M 500K Mar/2026
Merck USD 3.86B 541M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Pfizer USD 4.51B 734M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Takeda JPY 491.34B 23.75B Mar/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
TG Therapeutics USD 148.84M 41.34M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Xencor USD 7.92M 2.91M Mar/2026